Furthermore, we conducted a reanalysis of human MMRd CRC scRNAseq patient data, focused on patients who either achieved a complete response or did not completely respond to anti-PD-1 therapy, with examination of underlying immune profiles (Figure 1 G/H, Extended Figure 5) 17. Here, PDCD1 is linked to colorectal carcinoma.